Masimo Corporation (MASI) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED 2026
What happened to Masimo Corporation (MASI) stock?
Masimo Corporation (MASI) no longer trades on public markets. It was delisted in June 2026. The figures below are historical and are not a current quote.
P/E 124.97 means the share price is 124.97 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $9.42B is the value of all shares combined. Beta 1.20: the stock has moved about 20% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Masimo Corporation (MASI). Masimo Corporation develops and markets noninvasive patient monitoring technologies and hospital automation solutions. Their signal extraction technology (SET) and rainbow SET platforms are used in hospitals and other healthcare settings worldwide. Market cap: $9.42B, Sector: Healthcare.
Last analyzed: May 9, 2026MASI stock analysis for 2026: The stored analyst price target for Masimo Corporation is $176.00; its date is unknown, so no upside or downside is derived from it against the current price of $179.95. Key factors: analyst coverage, company fundamentals.
These figures come from statements filed 12 months ago — the most recent this company has published.
MASI: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Masimo Corporation (MASI) Healthcare & Pipeline Overview
Masimo Corporation is a global leader in noninvasive patient monitoring, offering advanced pulse oximetry and hospital automation solutions. Its signal extraction technology and rainbow SET platform differentiate it within the medical devices sector, addressing the limitations of conventional monitoring and expanding into diverse healthcare settings.
What Is the Investment Thesis for MASI?
Masimo Corporation presents a notable research candidate based on its leadership in noninvasive patient monitoring and its expanding portfolio of hospital automation solutions. The company's proprietary SET and rainbow SET technologies provide a competitive edge, driving adoption in hospitals and other healthcare settings. With a market capitalization of $9.42B and a P/E ratio of 124.97, Masimo's valuation reflects its growth potential. Key catalysts include the continued expansion of its hospital automation platform and the introduction of new monitoring technologies. However, investors should be aware of potential risks such as competition from established medical device companies and regulatory hurdles. Masimo's gross margin of 61.7% indicates strong pricing power and efficient operations.
Based on FMP financials and quantitative analysis
MASI Key Highlights
Market Cap of $9.42B reflects Masimo's significant presence in the medical device industry.
- P/E ratio of 124.97 suggests investors anticipate future earnings growth.
- Gross Margin of 61.7% demonstrates efficient operations and strong pricing power.
- Profit Margin of 4.9% indicates areas for potential improvement in operational efficiency.
- Beta of 1.20 suggests the stock is more volatile than the overall market.
Who Are MASI's Competitors?
MASI is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MOH Molina Healthcare, Inc. | $200.28 | +3.17% | $10.5B | 715-pillar |
| BAX Baxter International Inc. | $24.18 | -0.86% | $12.5B | 535-pillar |
| ABVX Abivax S.A. | $115.95 | -2.94% | $8.51B | 555-pillar |
| HSIC Henry Schein, Inc. | $87.80 | -0.19% | $10.0B | 705-pillar |
| ATR AptarGroup, Inc. | $121.64 | -0.38% | $7.76B | 755-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MASI's Key Strengths?
Proprietary SET and rainbow SET technologies
- Strong brand reputation
- Integrated hospital automation platform
- Extensive distribution network
What Are MASI's Weaknesses?
High P/E ratio may indicate overvaluation
- Profit margin could be improved
- Reliance on hospital spending
- Competition from established medical device companies
What Could Drive MASI Stock Higher?
Launch of new monitoring technologies and sensors.
- Expansion of the Hospital Automation platform into new hospitals and healthcare systems.
- Increasing adoption of Masimo's products in emerging markets.
- Strategic partnerships with other healthcare technology companies.
What Are the Key Risks for MASI?
Rich valuation — a P/E of 124.97 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Competition from established medical device companies.
- Regulatory hurdles and delays in product approvals.
- Economic downturns and reduced hospital spending.
- Patent expirations and potential for generic competition.
- Supply chain disruptions affecting manufacturing and distribution.
What Are the Growth Opportunities for MASI?
- Expansion of Hospital Automation Platform: Masimo's Hospital Automation platform, including Patient SafetyNet and UniView, offers significant growth potential by integrating patient monitoring data with clinical workflows. Masimo's competitive advantage lies in its ability to seamlessly integrate its monitoring technologies with its automation platform, providing a comprehensive solution for hospitals.
- Penetration of Emerging Markets: Emerging markets represent a significant growth opportunity for Masimo, as healthcare systems in these regions increasingly adopt advanced patient monitoring technologies. The demand for noninvasive monitoring solutions is growing in countries with expanding healthcare infrastructure and rising healthcare expenditure. Masimo can leverage its existing distribution network and OEM partnerships to penetrate these markets and establish a strong presence.
- Development of New Monitoring Technologies: Masimo's commitment to innovation drives the development of new monitoring technologies that address unmet clinical needs. The company's research and development efforts focus on expanding the capabilities of its rainbow SET platform and exploring new applications for its SedLine brain function monitoring technology. The introduction of new monitoring parameters and solutions can drive revenue growth and strengthen Masimo's competitive position.
- Expansion into Consumer Healthcare: Masimo's e-commerce site, masimopersonalhealth.com, provides a platform for expanding into the consumer healthcare market. The demand for personal health monitoring devices is growing, driven by increasing awareness of preventive healthcare and the availability of user-friendly technologies. Masimo can leverage its expertise in noninvasive monitoring to develop and market consumer-focused products, such as wearable pulse oximeters and sleep monitors.
- Strategic Acquisitions and Partnerships: Masimo can pursue strategic acquisitions and partnerships to expand its product portfolio, enter new markets, and enhance its technological capabilities. Acquisitions of companies with complementary technologies or established market positions can accelerate Masimo's growth and strengthen its competitive advantage. Partnerships with healthcare providers and technology companies can facilitate the integration of Masimo's solutions into clinical workflows and expand its reach.
What Are MASI's Competitive Advantages?
- Proprietary Masimo SET and rainbow SET technologies provide a competitive advantage in pulse oximetry.
- Strong brand reputation for accuracy and reliability in patient monitoring.
- Extensive patent portfolio protects its core technologies.
- Integrated hospital automation platform enhances customer value and creates switching costs.
- Established distribution network and OEM partnerships provide broad market access.
What Does MASI Do?
Masimo Corporation, founded in 1989 and headquartered in Irvine, California, is a global medical technology company that develops, manufactures, and markets a range of noninvasive patient monitoring technologies and hospital automation solutions. The company's core innovation lies in its Masimo Signal Extraction Technology (SET) pulse oximetry, designed to overcome the limitations of conventional pulse oximetry by accurately measuring oxygen saturation even during patient motion and low perfusion. This technology forms the basis of many of Masimo's products, which are used in hospitals, emergency medical services, home care, and other healthcare settings. Masimo's product portfolio includes the rainbow SET platform, which expands on the capabilities of SET by noninvasively monitoring multiple hemoglobin parameters, including oxygen saturation, pulse rate, perfusion index, and respiration rate. This platform also enables the monitoring of hemoglobin concentration, carboxyhemoglobin, and methemoglobin. Beyond pulse oximetry, Masimo offers SedLine brain function monitoring technology, capnography and gas monitoring products, O3 regional oximetry for tissue oxygen saturation measurement, and hemodynamic monitoring solutions. The company's Masimo Hospital Automation platform integrates these monitoring technologies with patient surveillance and data management systems, such as Patient SafetyNet and UniView, to improve patient safety and clinical workflows. Masimo distributes its products through a direct sales force, distributors, and original equipment manufacturer (OEM) partners, reaching a diverse customer base across the healthcare spectrum. The company also sells non-medical/consumer products through its e-commerce site, masimopersonalhealth.com.
What Products and Services Does MASI Offer?
- Develops and markets noninvasive patient monitoring technologies.
- Offers Masimo SET pulse oximetry for accurate oxygen saturation measurement.
- Provides Masimo rainbow SET platform for monitoring multiple hemoglobin parameters.
- Offers SedLine brain function monitoring technology.
- Develops capnography and gas monitoring products.
- Provides O3 regional oximetry for tissue oxygen saturation measurement.
- Offers hemodynamic monitoring solutions.
- Develops and markets hospital automation platforms.
How Does MASI Make Money?
- Sells noninvasive patient monitoring devices and sensors.
- Generates revenue from the sale of hospital automation software and services.
- Partners with original equipment manufacturers (OEMs) to integrate its technologies into their products.
- Distributes products through a direct sales force and distributors.
- Sells non-medical/consumer products through its e-commerce site.
What Industry Does MASI Operate In?
Masimo Corporation operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced patient monitoring technologies. The global market for patient monitoring devices is expected to grow, driven by factors such as an aging population, rising prevalence of chronic diseases, and increasing adoption of remote patient monitoring solutions. Masimo competes with established medical device companies, such as Baxter International Inc. (BAX), as well as specialized players in specific monitoring segments. The company's focus on noninvasive technologies and its integrated hospital automation platform position it to capitalize on the growing demand for patient safety and improved clinical workflows.
Who Are MASI's Key Customers?
- Hospitals and acute care facilities
- Emergency medical service providers
- Home care providers
- Long-term care facilities
- Physician offices
- Veterinarians
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 20 days old
- ● Latest filing 129 days ago
- ● Covered by analysts
Company Profile
Masimo Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Catherine Szyman. MASI has traded publicly since 2007.
MASI Revenue & Earnings Trend
In Q1 FY2026, MASI generated $403.6M in top-line revenue, marking a sequential decrease of 2.2%. The company recorded net income of $57.1M, with diluted EPS of $1.09. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, MASI averaged $0.36 in diluted EPS.
Masimo Corporation (MASI) Valuation Context
Valued at $9.42B, MASI is classified as a mid-cap stock.
Key Financial Metrics
Return on equity for Masimo Corporation stands at 9.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.6%, showing how much profit it generates from its asset base. MASI trades at a trailing price-to-earnings ratio of 124.97, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.8%, the inverse of the P/E and a quick read on earnings relative to price.
MASI Financials
Bull Case vs Bear Case
Bull Case
- Proprietary SET and rainbow SET technologies
- Strong brand reputation
- Integrated hospital automation platform
- Extensive distribution network
Bear Case
- High P/E ratio may indicate overvaluation
- Profit margin could be improved
- Reliance on hospital spending
- Competition from established medical device companies
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · May 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2026 | $404M | $57M | $1.09 |
| Q4 FY2025 | $413M | $68M | $1.26 |
| Q3 FY2025 | $372M | -$100M | -$1.85 |
| Q2 FY2025 | $371M | $51M | $0.94 |
Q1 FY2026 · filed 5 May 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
MASI Latest News
No recent news available for MASI.
Leadership: Catherine Szyman
CEO
Catherine Szyman is the CEO of Masimo Corporation, leading a workforce of 3600 employees. She has extensive experience in the medical device industry, with a background in engineering and product development. Prior to becoming CEO, she held various leadership positions within Masimo, overseeing research and development, operations, and commercial strategy. Her expertise spans across multiple areas of the business, providing a comprehensive understanding of the company's operations and market dynamics. She is known for her focus on innovation and her commitment to improving patient outcomes through advanced monitoring technologies.
Track Record: Under Catherine Szyman's leadership, Masimo has continued to expand its product portfolio and strengthen its market position in noninvasive patient monitoring. She has overseen the development and launch of new monitoring technologies, as well as the expansion of the company's hospital automation platform. Her strategic decisions have contributed to Masimo's revenue growth and profitability. She has also focused on fostering a culture of innovation and collaboration within the company.
MASI Healthcare Stock FAQ
What happened to Masimo Corporation (MASI) stock?
Masimo Corporation (MASI) no longer trades on public markets. It was delisted in June 2026. The figures below are historical and are not a current quote.
Can I still buy MASI shares?
No. MASI stopped trading on public markets in June 2026, so the shares are not available through a broker. Anything you see quoted for MASI elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MASI stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Masimo Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Masimo Corporation do?
Masimo Corporation is a global medical technology company that specializes in the development, manufacture, and marketing of noninvasive patient monitoring technologies and hospital automation solutions.
What do analysts say about MASI stock?
Analyst coverage of Masimo Corporation (MASI) typically focuses on the company's growth prospects in the patient monitoring market, its competitive position, and its financial performance. Key valuation metrics such as the P/E ratio and gross margin are closely scrutinized.
What are the main risks for MASI?
Masimo Corporation faces several key risks, including competition from established medical device companies such as Baxter International Inc. (BAX), which offer similar patient monitoring solutions. Regulatory hurdles and delays in product approvals can also impact the company's growth prospects.
How does Masimo Corporation navigate regulatory approval processes?
Masimo Corporation navigates regulatory approval processes, primarily with the FDA in the United States and similar bodies globally, by maintaining rigorous quality control standards and conducting thorough clinical trials to demonstrate the safety and efficacy of its devices.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest available reporting period.